Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Tau Mutations Serve as a Novel Risk Factor for Cancer.

Rossi G, Redaelli V, Contiero P, Fabiano S, Tagliabue G, Perego P, Benussi L, Bruni AC, Filippini G, Farinotti M, Giaccone G, Buiatiotis S, Manzoni C, Ferrari R, Tagliavini F.

Cancer Res. 2018 Jul 1;78(13):3731-3739. doi: 10.1158/0008-5472.CAN-17-3175. Epub 2018 May 24.

2.

Cellular and molecular modifier pathways in tauopathies: the big picture from screening invertebrate models.

Hannan SB, Dräger NM, Rasse TM, Voigt A, Jahn TR.

J Neurochem. 2016 Apr;137(1):12-25. doi: 10.1111/jnc.13532. Epub 2016 Feb 11. Review.

3.

Mutations in MAPT give rise to aneuploidy in animal models of tauopathy.

Rossi G, Conconi D, Panzeri E, Paoletta L, Piccoli E, Ferretti MG, Mangieri M, Ruggerone M, Dalprà L, Tagliavini F.

Neurogenetics. 2014 Mar;15(1):31-40. doi: 10.1007/s10048-013-0380-y. Epub 2013 Nov 12.

4.

Mutations in MAPT gene cause chromosome instability and introduce copy number variations widely in the genome.

Rossi G, Conconi D, Panzeri E, Redaelli S, Piccoli E, Paoletta L, Dalprà L, Tagliavini F.

J Alzheimers Dis. 2013;33(4):969-82. doi: 10.3233/JAD-2012-121633.

PMID:
23047372
5.

Frontotemporal lobar degeneration: old knowledge and new insight into the pathogenetic mechanisms of tau mutations.

Rossi G, Tagliavini F.

Front Aging Neurosci. 2015 Oct 14;7:192. doi: 10.3389/fnagi.2015.00192. eCollection 2015. Review.

6.

Different mutations at V363 MAPT codon are associated with atypical clinical phenotypes and show unusual structural and functional features.

Rossi G, Bastone A, Piccoli E, Morbin M, Mazzoleni G, Fugnanesi V, Beeg M, Del Favero E, Cantù L, Motta S, Salsano E, Pareyson D, Erbetta A, Elia AE, Del Sorbo F, Silani V, Morelli C, Salmona M, Tagliavini F.

Neurobiol Aging. 2014 Feb;35(2):408-17. doi: 10.1016/j.neurobiolaging.2013.08.004. Epub 2013 Sep 7.

PMID:
24018212
7.

The role of tau (MAPT) in frontotemporal dementia and related tauopathies.

Rademakers R, Cruts M, van Broeckhoven C.

Hum Mutat. 2004 Oct;24(4):277-95. Review.

PMID:
15365985
8.

Mutations causing neurodegenerative tauopathies.

Goedert M, Jakes R.

Biochim Biophys Acta. 2005 Jan 3;1739(2-3):240-50. Review.

9.

Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies.

Forrest SL, Kril JJ, Stevens CH, Kwok JB, Hallupp M, Kim WS, Huang Y, McGinley CV, Werka H, Kiernan MC, Götz J, Spillantini MG, Hodges JR, Ittner LM, Halliday GM.

Brain. 2018 Feb 1;141(2):521-534. doi: 10.1093/brain/awx328.

10.

[Animal models of tauopathies].

Higuchi M.

Rinsho Shinkeigaku. 2006 Nov;46(11):928-30. Japanese.

PMID:
17432223
11.

New insights into genetic and molecular mechanisms of brain degeneration in tauopathies.

Forman MS, Lee VM, Trojanowski JQ.

J Chem Neuroanat. 2000 Dec;20(3-4):225-44. Review.

PMID:
11207421
12.

Untangling the tauopathies: Current concepts of tau pathology and neurodegeneration.

Ling H.

Parkinsonism Relat Disord. 2018 Jan;46 Suppl 1:S34-S38. doi: 10.1016/j.parkreldis.2017.07.031. Epub 2017 Aug 1. Review.

PMID:
28789904
13.

V363I and V363A mutated tau affect aggregation and neuronal dysfunction differently in C. elegans.

Morelli F, Romeo M, Barzago MM, Bolis M, Mattioni D, Rossi G, Tagliavini F, Bastone A, Salmona M, Diomede L.

Neurobiol Dis. 2018 Sep;117:226-234. doi: 10.1016/j.nbd.2018.06.018. Epub 2018 Jun 22.

PMID:
29936232
14.

Tau protein in familial and sporadic diseases.

Yancopoulou D, Spillantini MG.

Neuromolecular Med. 2003;4(1-2):37-48. Review.

PMID:
14528051
15.

A new function of microtubule-associated protein tau: involvement in chromosome stability.

Rossi G, Dalprà L, Crosti F, Lissoni S, Sciacca FL, Catania M, Di Fede G, Mangieri M, Giaccone G, Croci D, Tagliavini F.

Cell Cycle. 2008 Jun 15;7(12):1788-94. Epub 2008 Jun 25.

PMID:
18583940
16.

Frequency of tau mutations in familial and sporadic frontotemporal dementia and other tauopathies.

Stanford PM, Brooks WS, Teber ET, Hallupp M, McLean C, Halliday GM, Martins RN, Kwok JB, Schofield PR.

J Neurol. 2004 Sep;251(9):1098-104.

PMID:
15372253
17.

Tau alteration and neuronal degeneration in tauopathies: mechanisms and models.

Brandt R, Hundelt M, Shahani N.

Biochim Biophys Acta. 2005 Jan 3;1739(2-3):331-54. Review.

18.

Invited review: Neuropathology of tauopathies: principles and practice.

Kovacs GG.

Neuropathol Appl Neurobiol. 2015 Feb;41(1):3-23. doi: 10.1111/nan.12208. Review.

PMID:
25495175
19.

Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration.

Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, White CL 3rd, Schneider JA, Grinberg LT, Halliday G, Duyckaerts C, Lowe JS, Holm IE, Tolnay M, Okamoto K, Yokoo H, Murayama S, Woulfe J, Munoz DG, Dickson DW, Ince PG, Trojanowski JQ, Mann DM; Consortium for Frontotemporal Lobar Degeneration.

Acta Neuropathol. 2007 Jul;114(1):5-22. Epub 2007 Jun 20.

20.

Frontotemporal lobar degeneration. An update on clinical, pathological and genetic findings.

Tolnay M, Probst A.

Gerontology. 2001 Jan-Feb;47(1):1-8. Review.

PMID:
11244285

Supplemental Content

Support Center